Logo

Biohaven Reports Results of Zavegepant in P-III Study for the Treatment of Migraine

Share this

Biohaven Reports Results of Zavegepant in P-III Study for the Treatment of Migraine

Shots:

  • The P-III study evaluates zavegepant (IN) vs PBO in 1405 adult patients with migraine at 94 sites in the US
  • The P-III study meets its co-primary EPs of pain freedom (24% vs 15%) & freedom from the bothersome symptom (40% vs 31%) @ 2hrs. & showed ultra-rapid pain relief as early as 15min. & sustained efficacy @48hrs. after a single IN dose. The therapy showed superiority over PBO across 15 prespecified primary & secondary outcome measures, favorable safety & tolerability profile that was consistent with prior clinical trial
  • The company plans to file an NDA for zavegepant with the US FDA in Q1’22, based on P-II/III trial results. If approved, it will be 1st CGRP receptor antagonist for migraine

Ref: Biohaven | Image: Biohaven 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions